Daniel Stauder
Stock Analyst at Citizens
(4.22)
# 441
Out of 5,090 analysts
20
Total ratings
63.16%
Success rate
14.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Stauder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AORT Artivion | Maintains: Market Outperform | $47 → $53 | $44.59 | +18.86% | 7 | Nov 7, 2025 | |
| ATRC AtriCure | Reiterates: Market Outperform | $60 | $39.86 | +50.53% | 6 | Apr 30, 2025 | |
| STIM Neuronetics | Maintains: Market Outperform | $3 → $7 | $1.35 | +418.52% | 1 | Mar 5, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Buy | $105 → $110 | $84.53 | +30.13% | 4 | Feb 28, 2025 | |
| AXON Axon Enterprise | Reiterates: Market Outperform | $725 | $550.95 | +31.59% | 1 | Feb 26, 2025 | |
| AVNS Avanos Medical | Reiterates: Market Perform | n/a | $11.26 | - | 1 | May 7, 2024 |
Artivion
Nov 7, 2025
Maintains: Market Outperform
Price Target: $47 → $53
Current: $44.59
Upside: +18.86%
AtriCure
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $39.86
Upside: +50.53%
Neuronetics
Mar 5, 2025
Maintains: Market Outperform
Price Target: $3 → $7
Current: $1.35
Upside: +418.52%
LeMaitre Vascular
Feb 28, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $84.53
Upside: +30.13%
Axon Enterprise
Feb 26, 2025
Reiterates: Market Outperform
Price Target: $725
Current: $550.95
Upside: +31.59%
Avanos Medical
May 7, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $11.26
Upside: -